Go-AI has assembled an enviable team of professionals with strong industry expertise and experience in oncology, virology, drug development, advanced medical engineering, clinical research management, experience in pre clinical and clinical studies, investment banking, and application of AI.

Despite the successful invitro study in 2005 with the original Nanobomb against BT474 Breast Cancer Cells, Nanotherapy Plus will conduct its own invitro studies on human cancer cell lines for a number of cancer types, followed by conduct of preclinical animal studies and clinical trials in Hong Kong, China and/or in Australia.

These studies will be designed to demonstrate safety and efficacy, inventiveness and novelty of our Combination Therapy against a range of cancer types.

To expedite commercialization of Nanotherapy Plus’s Combination Cancer Therapy, Go-AI will be offering product distribution licenses, direct to government pre-purchase orders, and scaling up production by partnering with pharmaceutical manufacturers.